There are 3164 resources available
Session conclusion and outline of next steps: DC community panel discussion
Presenter: Anna Reyners
Session: 9th ESMO Designated Centres of Integrated Oncology and Palliative Care session and awards: Specific considerations for integration of oncology and palliative care
Resources:
Slides
Webcast
1726MO - Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase I study
Presenter: Breelyn Wilky
Session: Mini oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
Invited Discussant 1148MO and 1149MO
Presenter: Sara De Dosso
Session: Mini oral session: NETs and endocrine tumours
Resources:
Slides
Webcast
Designated Centres Awards
Presenter: Anna Reyners, Jayne Wood
Session: 9th ESMO Designated Centres of Integrated Oncology and Palliative Care session and awards: Specific considerations for integration of oncology and palliative care
Resources:
Slides
Webcast
1727MO - Can proteomics predict metastatic relapse in leiomyosarcoma (LMS)? Development of an 8 protein signature in a >350 sample study including a validation cohort
Presenter: Elizabeth Connolly
Session: Mini oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
Invited Discussant 1725MO, 1726MO and 1727MO
Presenter: Cesar Serrano
Session: Mini oral session: Sarcoma
Resources:
Webcast
LBA48 - CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
Presenter: Glenwood Goss
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Abstract
Slides
Webcast
440O - First in human study of the mRNA-based cancer vaccine CVGBM in patients (pts) with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma (GBM): First results from the dose escalation phase
Presenter: Ghazaleh Tabatabai
Session: Proffered paper session: CNS tumours
Resources:
Abstract
Slides
Webcast
799MO - The primary results from a randomized double-blind phase II study of rovadicitinib versus hydroxyurea in patients with myelofibrosis
Presenter: Ling Pan
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Slides
Webcast
Are cytotoxics still the next option?
Presenter: Elena Castro
Session: Therapeutic options beyond AR pathway inhibitors: What do we choose next?
Resources:
Slides
Webcast